Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Common Equity (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Common Equity for 9 consecutive years, with $130.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 41.48% year-over-year to $130.3 million, compared with a TTM value of $130.3 million through Dec 2025, up 41.48%, and an annual FY2025 reading of $130.3 million, up 41.48% over the prior year.
  • Common Equity was $130.3 million for Q4 2025 at Puma Biotechnology, up from $115.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $130.3 million in Q4 2025 and bottomed at -$10.9 million in Q3 2021.
  • Average Common Equity over 5 years is $48.1 million, with a median of $34.6 million recorded in 2023.
  • The sharpest move saw Common Equity crashed 2311.04% in 2021, then surged 983.4% in 2022.
  • Year by year, Common Equity stood at -$2.4 million in 2021, then soared by 983.4% to $21.6 million in 2022, then surged by 147.33% to $53.4 million in 2023, then surged by 72.38% to $92.1 million in 2024, then surged by 41.48% to $130.3 million in 2025.
  • Business Quant data shows Common Equity for PBYI at $130.3 million in Q4 2025, $115.3 million in Q3 2025, and $104.7 million in Q2 2025.